Hubei Biocause Pharmaceutical (000627.SZ) subsidiary CHINA BEST life insurance company's accumulated premium income from January to August reached approximately 29.03 billion yuan.

Hubei Biocause Pharmaceutical (000627.SZ) announces that its controlling subsidiary, CHINA BEST Life Insurance Co., Ltd., is proceeding with business development in accordance with the overall strategy of "firmly transitioning for development, highlighting value growth, comprehensively improving capabilities, and moving towards a mature insurance enterprise". The company is focusing on value-based business, continuously promoting business structure optimization. From January 1, 2024 to August 31, 2024, the accumulated original insurance premium income is approximately 29.03 billion yuan.